Navigation Links
Rigel Announces Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

elopment programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the timing of results of Rigel's clinical development of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Ryan D. Maynard

Phone: 650.624.1284

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com

STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Revenues:

Contract revenues from

collaborations $8,000
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion ... trial of Cotara® in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a radioisotope ... Cotara specifically targets cells at the center of ...
(Date:12/2/2009)... TechConnect World, an event bringing together the ... cleantech, nanotech, biotech and MEMS, announced the December ... ,, Now in its 14th year, TechConnect World, ... Institute (NSTI), and the Clean Technology and Sustainable ...
(Date:12/2/2009)... 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the ... pharmaceutical company,specializing in the development, manufacturing, and marketing ... announced that 105 of,its drugs have been included ... issued by China,s Ministry of Human Resources and ...
(Date:12/2/2009)... to the National Institute of Health, 40 percent to 45 ... of diabetic retinopathy. Diabetic retinopathy, damage to the retina ... blindness in people with diabetes and is one of the ... percent of all patients who,ve had diabetes for 10 years ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... third quarter 2007 to $201 million, SAN DIEGO, ... today reported financial results for the quarter ended,September 30, ... the third quarter, including net product sales of $201.4 ... Net loss for the quarter ended,September 30, 2008 was ...
... to Additional Capital Will Enable Revenue Growth, ... Bulletin Board: BLFS), a leading developer and marketer ... tissues, and organs, today announced that it reached ... to increase the Company,s,existing credit facility from $5 ...
Other Biology Technology:American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Amylin Pharmaceuticals Reports Third Quarter Financial Results 2Amylin Pharmaceuticals Reports Third Quarter Financial Results 3Amylin Pharmaceuticals Reports Third Quarter Financial Results 4Amylin Pharmaceuticals Reports Third Quarter Financial Results 5Amylin Pharmaceuticals Reports Third Quarter Financial Results 6Amylin Pharmaceuticals Reports Third Quarter Financial Results 7Amylin Pharmaceuticals Reports Third Quarter Financial Results 8BioLife Solutions Credit Facility Increased to $9 Million 2
(Date:12/5/2009)... research into venom produced by snakes and spiders, venomous ... mystery. Now, a study of 158 catfish species, published ... , has catalogued the presence of venom glands and ... from the University of Michigan, USA, carried out the ... to elucidate the diversity and distribution of venomous catfish. ...
(Date:12/4/2009)... Ore. According to an analysis of statewide data ... than $50,000 a year were more than three times ... providers because of their insurance status during pregnancy and ... was also three times more likely among mothers with ...
(Date:12/4/2009)... electroencephalogram (EEG) is widely used by physicians and scientists ... However, it has remained largely unknown whether the electrodes ... is happening inside the brain. Scientists at the Max ... now found a crucial link between the activity generated ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2How to read brain activity? 2Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 1Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 2Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 3Michigan Health 26 Hospital Association Elects 2009 Officers and Board Members 49957 1Michigan Health 26 Hospital Association Elects 2009 Officers and Board Members 49957 2Bone Therapy May Not Always Need Monitoring 49955 1Bone Therapy May Not Always Need Monitoring 49955 2
... Special Areas of Conservation throughout the UK, including Dorset, ... driving. The frequency range of pile driving noise could ... avoid predators. This has the potential to affect their ... females and young calves might be particularly vulnerable ...
... days of winter, gardeners are known to count the days ... the same thing. , Addressing scientists here today (Aug. 9) ... University of Wisconsin-Madison researcher Richard Amasino described studies that have ... plants pace the seasons to bloom at the optimal time ...
... GmbH, a pioneer and leader in the analysis ... base of transcription factors (TF). , It contains ... related literature, more than 27.000 known TF ?gene ... modules), and weight matrix descriptions for the DNA ...
Other Biology News:South Pacific plant may be missing link in evolution of flowering plants 2Genetic snooze button governs timing of spring flowers 2Genetic snooze button governs timing of spring flowers 3
... Glycine Transporter 2, Neuronal (GLYT2). The antiserum ... the central nervous system. The staining pattern ... described using in situ hybridization with probes ... been described for glycinergic neurons. Preabsorption of ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
... Reacts with an early protein. ... 3 hours post-infection exhibiting an ... peak intensity between 6-24 hours. ... intense coarsely granular staining. ...
Biology Products: